



(fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder



Welcome to the Digihaler® Dashboard

Inhaler event data in one accessible place

The Digihaler Dashboard is a secure, online tool that enables you to view patients' inhaler event data. **If the patient consents to share,** data is sent from the Digihaler Mobile App to the Dashboard, which may allow healthcare providers to have more informed treatment discussions with their patients.^{1,2}

The Digihaler Dashboard helps you to:

- Securely access data from a single patient or multiple patients
- See when patients use their ProAir Digihaler, AirDuo Digihaler, and/or ArmonAir Digihaler, and assess inspiratory flow rates
- Access daily, weekly, or monthly reports

With inhaler event information accessible to you and your team,

you may be able to make more informed treatment decisions for your patients.^{1,2}

INDICATIONS FOR PROAIR® DIGIHALER®

ProAir® Digihaler® (albuterol sulfate) Inhalation Powder is indicated in patients ≥4 years of age for the treatment or prevention of bronchospasm with reversible obstructive airway disease and in patients ≥4 years of age for the prevention of exercise-induced bronchospasm.

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER®

• **Contraindications:** ProAir Digihaler (albuterol sulfate) Inhalation Powder is contraindicated in patients with hypersensitivity to albuterol or patients with a severe hypersensitivity to milk proteins. Rare cases of hypersensitivity reactions, including urticaria, angioedema, and rash have been reported after the use of albuterol sulfate. There have been reports of anaphylactic reactions in patients using inhalation therapies containing lactose

INDICATIONS FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER®

ArmonAir® Digihaler® (fluticasone propionate) inhalation powder is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older.

<u>Limitation of Use:</u> ArmonAir Digihaler is not indicated for the relief of acute bronchospasm.

AirDuo[®] Digihaler[®] (fluticasone propionate and salmeterol) inhalation powder is indicated for the treatment of asthma in patients aged 12 years and older. AirDuo Digihaler is only for patients uncontrolled on an inhaled corticosteroid (ICS) or whose disease severity clearly warrants an ICS/Long-acting beta2- agonist (LABA).

<u>Limitation of Use:</u> AirDuo Digihaler is not indicated for the relief of acute bronchospasm.

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER®

- Contraindications: ArmonAir Digihaler and AirDuo Digihaler are contraindicated in:
 - » Primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive measures
 - » Patients with known severe hypersensitivity to milk proteins or any ingredients of ArmonAir Digihaler or AirDuo Digihaler

Please see additional Safety Information throughout this brochure and full Prescribing Information for <u>ProAir Digihaler ArmonAir Digihaler</u> and <u>AirDuo Digihaler</u>.

Table of Contents

For All Dashboard Users

Section 1: Account Basics

- The Dashboard Team
- Signing Up
- Joining Multiple Programs
- Logging Out
- Resetting Your Password

Section 2: Inviting Patients

- Adding Patients to the Dashboard
- Inviting Patients

Section 3: Navigating the Patient List

- Viewing the Patient List
- Filtering the Patient List
- Removing Patients from your Program

Section 4: Viewing Patient Details

- Patient Details
- Understanding the Patient Details Screen
- The Digihaler® Events Chart
- The Recorded Digihaler® Events Table
- Digihaler® Connectivity
- Accessing Detailed Data
- The Peak Inspiratory Flow Chart
- The Inhalation Volume Chart

Section 5: Exporting Patient Data

- Setting up an Export
- Applying Filters

Section 6: Support and Troubleshooting

For Dashboard Admins and Super Admins

Section 7: Inviting Teammates

- Managing your program together
- Changing the Role of a Teammate
- Managing Pending Invitations
- Exporting an Audit Log

Section 8: Program Settings

- Program Settings
- Configuring Filters
- Using Filters

Section 1: Account Basics

The Dashboard Team (1 of 2)

You will have a program specific to your department within the Digihaler® Dashboard. Your program will be run by a team made up of three different types of users who are responsible for specific administrative roles.

Super Administrator

Primary responsibilities:

- Requesting Dashboard access from a Teva Representative
- Inviting new Super Administrators, Administrators, and Dashboard Users—Super
 Administrators should choose roles that are the best fit for each member
- Inviting patients to participate in the program
- Removing team members if needed
- Changing existing users' roles if needed

Please Note that there can be multiple Super Administrators, since each healthcare facility is different in structure and process. For instance, a Super Administrator can be a member of the facility's IT department, as well as a head doctor of a small practice.

Administrator

Primary responsibilities:

- Assisting the Super Administrators in managing the team's specific program
- Inviting, removing, and managing other Administrators and Dashboard Users
- Identifying, inviting, and adding patients to Patient List
- Promoting Dashboard Users to Admins if needed

Dashboard User

Primary responsibilities:

- Patient care—note that Dashboard Users have full access to inhaler event data and will likely be a healthcare provider
- Inviting and removing patients
- Viewing Patient List
- Reviewing and assessing patient inhaler event data

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES PROGRAM SETTINGS

• • • • • • • • • • •

The Dashboard Team (2 of 2)

Here is a comparison chart of the roles and permissions for each team member:

	Super Administrator	Administrator	Dashboard User
View Patient List	•		
View Patient Details			
Invite Patient			
Remove Patient			
View Team List			
Invite Super Admin user			
Invite Admin user			
Invite Dashboard user	•		
Remove Admin user			
Remove Dashboard user			
Using Filters			
Configuring Filters			
Download Audit Log			

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES PROGRAM SETTINGS

• • • • • • • •

Signing Up (1 of 6)

1 You will be sent an invitation link by one of the members on your team.

Super Administrator

Administrator/Dashboard User

Super Admins are invited by a Teva representative or other Super Admins.

Admins and Dashboard Users are invited by an Admin or a Super Admin.

Your invitation link will direct you to the Digihaler® Dashboard's landing page (https://us.dhp.ehealth.teva/careprogram/welcome)

Welcome to the Digihaler Dashboard

To get started, please log into the dashboard.

Log in

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Signing Up (2 of 6)

- 3 Click "Login" where you'll be directed to a login screen
 - a. For your first time sign-in, click "Sign Up."
 - **b.** If it is not your first time, type in the email you have associated with your account and the password you have already created.




Log In	
New to Digihaler Dashboard? Sign Up	
Email	
Password	•
Remember me Only select this option on your private or private or private using a public or shared computer.	personal device. Do not use this if
Login	

Signing Up (3 of 6)

4 Click on "Sign Up" to create your login credentials

Log In

New to Digihaler Dashboard? Sign Up



ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING


INVITING TEAMMATES

Signing Up (4 of 6)

- Your invitation link will direct you to the Digihaler® Dashboard's landing page. You'll be prompted to:
 - a. Sign up using your first name, last name, email, and confirm email

Please Note that you must use the same email that your inviter has specified

- **b.** Create a password using a minimum of 8 characters, consisting of both uppercase and lowercase letters, and at least one number
- c. Click "Sign up"



ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING


INVITING TEAMMATES PROGRAM SETTINGS

.


Signing Up (5 of 6)

The next screen will prompt you to enter a One-Time Sign-in code. The code will be emailed to you to confirm that the email you have entered is valid.

A 6-digit code will be sent to the email you have associated with the program. Check your email for a message from "Teva Pharmaceuticals." If you do not see the email in your inbox, check your spam folder.



The email will contain a code for you to enter into the program screen's form field as shown here



Please Note

- You must enter the 6-digit code with no additional spaces. Entering a mistaken code will result in an expired PIN error code, and you will be sent a new one.
- The PIN expires after 10 minutes. You will no longer need the PIN for future logins if using the same device and browser.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS


EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Signing Up (6 of 6)

7 Once you complete the sign-up process, you will be prompted to join the program you were added to.



For Super Admins

Once the Super Administrator has created the program and set up their login credentials, they can begin to invite Administrators and Dashboard Users

For Admins

Once Administrators have set up their login credentials, they can begin to <u>invite Dashboard Users</u> or <u>patients</u>


For Dashboard Users

Once Dashboard Users have set up their login credentials, they can begin to <u>invite patients</u> and view their data after the patient consents to share via the app.

Joining Multiple Programs (1 of 2)

You may be invited to multiple programs if you are a part of more than one practice, or charged with managing more than one team.

Your sign up process will follow the same instructions as above, but you will be prompted to choose the program you would like to view immediately after sign-in.



If you are invited to another program, you will see upon login, the additional program with a "Join" button.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST


VIEWING PATIENT DETAILS EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Joining Multiple Programs (2 of 2)

If you want to switch programs or join another program **while already logged into the Dashboard,** click the down arrow next to the program name in the left hand navigation menu and select the program you'd like to switch to, or select "Pending Invitations" to join a program to which you have been invited.



ACCOUNT BASICS

INVITING PATIENTS NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA


SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Logging Out

To log out, simply select "Logout" from the bottom of the left hand navigation menu. You will be redirected to the landing login page.

You will be automatically logged out after 30 minutes of inactivity.



ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING


INVITING TEAMMATES PROGRAM SETTINGS

.

Resetting Your Password

If you've forgotten your password:

- a. Select "Forgot Password" from the main Login screen.
- **b.** Enter the email associated with your Dashboard account to start the password reset process.



An email will be sent to your email account. Click the link provided in the email and you will be directed to a new login screen where you can enter a new password and confirm. Your password will be reset for all future logins.

.

Section 2: Inviting Patients

Adding Patients to the Dashboard

The Digihaler® Dashboard allows doctors and patients to work together on care. When patients choose to share their inhaler event data with their healthcare provider, they can review this information together during consultations. **The information provided by the Digihaler Dashboard may support more informed conversations about treatment.**^{1,2,}

The Digihaler Dashboard incorporates industry-standard security and privacy protections.

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Paradoxical Bronchospasm: ProAir Digihaler can produce paradoxical bronchospasm that may be life-threatening. Discontinue ProAir Digihaler and institute alternative therapy if paradoxical bronchospasm occurs

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Serious Asthma-Related Events – Hospitalizations, Intubations, Death: Use of a LABA as monotherapy (without an ICS) for asthma is associated with an increased risk of asthma-related death. Available data from controlled clinical trials also suggest that use of LABA as monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patients. These findings are considered a class effect of LABA monotherapy. When LABA are used in fixed-dose combination with ICS (such as AirDuo Digihaler), data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING


INVITING TEAMMATES PROGRAM SETTINGS

• • • • •

Inviting Patients (1 of 5)

After you've logged into your specific program, you'll be directed to your Patient List:

Please Note that you can switch between "Patient List" and "Team List" from the left hand navigation menu. To add Patients, ensure "Patient List" is selected. Only Admins and Super Admins will be able to view the Team List and Program Settings.



Please Note that the Dashboard will only display data for inhalers designated for your program and that have been registered by your patient. For instance, if your program has designated ProAir® Digihaler® only, you will only see data for that inhaler.

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Deterioration of Asthma:** Need for more doses of ProAir Digihaler than usual may be a marker of acute or chronic deterioration of asthma and requires reevaluation of treatment, such as possible need for anti-inflammatory treatment, e.g., corticosteroids

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• **Deterioration of Disease and Acute Episodes:** AirDuo Digihaler should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma. ArmonAir Digihaler and AirDuo Digihaler are not indicated for the relief of acute bronchospasm. An inhaled, short-acting beta2-agonist, not ArmonAir Digihaler or AirDuo Digihaler, should be used to relieve acute symptoms such as shortness of breath

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS


EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Inviting Patients (2 of 5)

The Patient List is where you can begin to invite participating patients.



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Use of Anti-Inflammatory Agents: ProAir Digihaler alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Avoid Excessive Use and Avoid Use with Other Long acting Beta2-Agonists: AirDuo Digihaler should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.

Patients using AirDuo Digihaler should not use another medicine containing a LABA (e.g., salmeterol, formoterol fumarate, arformoterol tartrate, indacaterol) for any reason

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS


EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Inviting Patients (3 of 5)

The Patient List is where you can begin to invite participating patients.



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Cardiovascular Effects: ProAir Digihaler, like other beta-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients, as measured by heart rate, blood pressure, and/or symptoms. If such effects occur, the drug may need to be discontinued. ProAir Digihaler, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• **Oropharyngeal Candidiasis** has occurred in patients treated with ArmonAir Digihaler or AirDuo Digihaler. Advise patients to rinse the mouth with water without swallowing following inhalation

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS


EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Inviting Patients (4 of 5)

The Patient List is where you can begin to invite participating patients.



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Do Not Exceed Recommended Dose:** Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Immunosuppression and Risks of Infections: Patients who use corticosteroids, such as found in AirDuo Digihaler and ArmonAir Digihaler are at risk for potential worsening of existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. A more serious or even fatal course of chickenpox or measles may occur in susceptible patients. Use with caution in patients with the above because of the potential for worsening of these infections

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS


EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Inviting Patients (5 of 5)

The Patient List is where you can begin to invite participating patients.



Please Note that the Dashboard will only display data for inhalers designated for your program and that have been registered by your patient. For instance, if your program has designated ProAir® Digihaler® only, you will only see data for that inhaler.

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Hypersensitivity Reactions including Anaphylaxis:** Immediate hypersensitivity reactions may occur after administration of albuterol sulfate, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. Hypersensitivity reactions including anaphylaxis, angioedema, pruritus, and rash have been reported with the use of therapies containing lactose, an inactive ingredient in ProAir Digihaler.

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Transferring Patients from Systemic Corticosteroid Therapy: Particular care is needed for patients who have been transferred from systemically active corticosteroids to ICS because deaths due to adrenal insufficiency have occurred in patients with asthma during and after transfer from systemic corticosteroids to less systemically available ICS.

Taper patients slowly from systemic corticosteroids if transferring to ArmonAir Digihaler or AirDuo Digihaler

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING


INVITING TEAMMATES PROGRAM SETTINGS

. . . .

Section 3: Navigating The Patient List

Viewing the Patient List (1 of 7)

Your Patient List is where you can access inhaler event data for each of your patients, organized by the medication they are prescribed. You can search for a patient by their name, and sort the list by name, date of birth, number of events, percentage of good inhalations, or time since all connected. The list provides an overarching view of patient data.



Please Note that the Dashboard will only display data for inhalers designated for your program and that have been registered by your patient. For instance, if your program has designated ProAir® Digihaler® only, you will only see data for that inhaler.

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Coexisting Conditions:** ProAir Digihaler, like all sympathomimetic amines, should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines.

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• **Hypercorticism and Adrenal Suppression** may occur with high doses of ICS, including fluticasone propionate, or at the recommended dose in susceptible individuals. If such changes occur, discontinue ArmonAir Digihaler or AirDuo Digihaler slowly

Please see additional Safety Information throughout this brochure and full Prescribing Information for <u>ProAir Digihaler ArmonAir Digihaler</u> and <u>AirDuo Digihaler</u>.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA


SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES PROGRAM SETTINGS

• • • • • • • • • • •

Viewing the Patient List (2 of 7)

The Patient List contains:



Please Note that the Dashboard will only display data for inhalers designated for your program and that have been registered by your patient. For instance, if your program has designated ProAir® Digihaler® only, you will only see data for that inhaler.

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Hypokalemia:** As with other beta-agonists, ProAir Digihaler may produce significant hypokalemia in some patients. The decrease is usually transient, not requiring supplementation

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• **Drug Interactions with Strong Cytochrome P450 3A4 Inhibitors:** The use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ritonavir, ketoconazole) with ArmonAir Digihaler or AirDuo Digihaler is not recommended because increased systemic corticosteroid adverse effects may occur; increased cardiovascular adverse effects may also occur with AirDuo Digihaler

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA


SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES PROGRAM SETTINGS

• • • • • • • • •

Viewing the Patient List (3 of 7)

The Patient List contains:



Please Note that the Dashboard will only display data for inhalers designated for your program and that have been registered by your patient. For instance, if your program has designated ProAir Digihaler only, you will only see data for that inhaler.

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Most common adverse reactions (≥1% and >placebo) are back pain, pain, gastroenteritis viral, sinus headache, urinary tract infection, nasopharyngitis, oropharyngeal pain and vomiting

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Paradoxical Bronchospasm and Upper Airway Symptoms: Paradoxical bronchospasm may occur. if bronchospasm occurs treat immediately with an inhaled, short-acting bronchodilator discontinue AirDuo Digihaler or ArmonAir Digihaler and institute alternative therapy

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS


EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Viewing the Patient List (4 of 7)

The Patient List contains:



Please Note that the Dashboard will only display data for inhalers designated for your program and that have been registered by your patient. For instance, if your program has designated ProAir® Digihaler® only, you will only see data for that inhaler.

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Drug Interactions:** Other short-acting sympathomimetic bronchodilators should not be used concomitantly with ProAir Digihaler

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Hypersensitivity Reactions, Including Anaphylaxis: Immediate hypersensitivity reactions (e.g., urticaria, angioedema, rash, bronchospasm, hypotension), including anaphylaxis, may occur after administration of ArmonAir Digihaler or AirDuo Digihaler. Discontinue ArmonAir Digihaler or AirDuo Digihaler if such reactions occur

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS


EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Viewing the Patient List (5 of 7)

The Patient List contains:



Please Note that the Dashboard will only display data for inhalers designated for your program and that have been registered by your patient. For instance, if your program has designated ProAir® Digihaler® only, you will only see data for that inhaler.

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

- Drug Interactions: (continued)
 - » Beta-Blockers: Beta-adrenergic-receptor blocking agents not only block the pulmonary effect of beta-agonists, such as ProAir Digihaler, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Cardiovascular and Central Nervous System Effects: The salmeterol component of AirDuo Digihaler, can be associated with excessive beta-adrenergic stimulation which could present as the following symptoms: seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, palpitation, nausea, dizziness, fatigue, malaise, and insomnia. Use with caution in patients with cardiac arrhythmias, hypertension, coronary insufficiency. Drug may need to be discontinued in certain patients.

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS NAVIGATING THE PATIENT LIST


VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Viewing the Patient List (6 of 7)



Please Note that the Dashboard will only display data for inhalers designated for your program and that have been registered by your patient. For instance, if your program has designated ProAir Digihaler only, you will only see data for that inhaler.

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

- **Drug Interactions:** (continued)
 - » **Diuretics:** Caution is advised in the coadministration of beta-agonists with non-potassium sparing diuretics (such as loop or thiazide diuretics). Consider monitoring potassium levels

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Reduction in Bone Mineral Density (BMD): Decreases in BMD have been observed with long-term administration of products containing ICS. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care when using ArmonAir Digihaler or AirDuo Digihaler

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS


EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Viewing the Patient List (7 of 7)

The Patient List contains:



Please Note that the Dashboard will only display data for inhalers designated for your program and that have been registered by your patient. For instance, if your program has designated ProAir® Digihaler® only, you will only see data for that inhaler.

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

- Drug Interactions: (continued)
 - » Digoxin: Carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and ProAir Digihaler

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• **Effect on Growth:** ICS may cause a reduction in growth velocity, Patients should be maintained on the lowest dose of inhaled corticosteroid that effectively controls their asthma. Monitor growth of pediatric patients receiving ArmonAir Digihaler and AirDuo Digihaler.

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING


INVITING TEAMMATES PROGRAM SETTINGS

• • • • • • • •

Filtering the Patient List

By default, the Patient List will display an unfiltered list with All Patients data. When managing larger populations of patients on the Dashboard, it may prove challenging to quickly identify specific patient cohorts. The filtering feature allows Admins and Super Admins to create custom filters that all users of the Dashboard can then leverage to identify patients that match defined criteria (See Section 8: Program Settings).

Custom filters will filter the list of patients based on how many events patients had that match criteria such as inhaler brand, time of day, or range of dates. Depending on whether the patient is over or under a certain threshold that matches the defined criteria, this will determine whether the patient is displayed on the filtered list or not.



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

- Drug Interactions: (continued)
 - » Monoamine Oxidase Inhibitors or Tricyclic Antidepressants: ProAir Digihaler should be administered with extreme caution to patients being treated with these agents, or within 2 weeks of discontinuation of these agents, because the action of albuterol on the cardiovascular system may be potentiated. Consider alternative therapy

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Glaucoma and Cataracts: Long-term use of ICS, including fluticasone propionate, a component of ArmonAir Digihaler and AirDuo Digihaler, may increase the risk for cataracts or glaucoma. Regular eye exams should be considered

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA


SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Removing Patients from your Program (1 of 3)

You are able to remove patients from your program via the "Patient Details" page. To do so:

- a. Go to the "Patient List" page
- **b.** Select the patient you want to remove



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Paradoxical Bronchospasm: ProAir Digihaler can produce paradoxical bronchospasm that may be life-threatening. Discontinue ProAir Digihaler and institute alternative therapy if paradoxical bronchospasm occurs

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Eosinophilic Conditions and Churg-Strauss Syndrome: Systemic eosinophilic conditions, such as Churg-Strauss syndrome, may occur when using ArmonAir Digihaler or AirDuo Digihaler. Be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA


SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES PROGRAM SETTINGS

.

Removing Patients from your Program (2 of 3)

You are able to remove patients from your program via the "Patient Details" page



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Deterioration of Asthma:** Need for more doses of ProAir Digihaler than usual may be a marker of acute or chronic deterioration of asthma and requires reevaluation of treatment, such as possible need for anti-inflammatory treatment, e.g., corticosteroids

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Coexisting Conditions: Use AirDuo Digihaler with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING


INVITING TEAMMATES PROGRAM SETTINGS

30 Days

Removing Patients from your Program (3 of 3)

When removing a patient, you will be prompted to confirm this action and warned that this operation cannot be undone. After confirmation, their name will disappear from the Patient List. Patients can also leave the program via the Digihaler® Mobile App, and there will be no notification that the patient has done so.

Please Note that the patient's inhaler event data is stored on the inhaler itself, and viewed in the Digihaler Mobile App. If the patient wishes to re-enroll in the program, you simply have to invite them again, and you will still be able to view their previous data after they consent to share.



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Use of Anti-Inflammatory Agents: ProAir Digihaler alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• **Hypokalemia and Hyperglycemia:** Beta-adrenergic agonist medicines may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. Decrease in serum potassium are usually transient, not requiring supplementation. Be alert to hypokalemia and hyperglycemia in patients using AirDuo Digihaler

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Section 4: Viewing Patient Details

Patient Details (1 of 2)

The Patient Details Screen includes details on inhaler events, such as time of use and inspiratory flow rates. Inhaler use is recorded as an event when a patient opens the cap or inhales. **The Patient Details Screen can help healthcare providers see a broad view of inhaler events, and assess trends or patterns over time.**This information may help inform treatment decisions during consultations with patients.

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Cardiovascular Effects: ProAir Digihaler, like other beta-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients, as measured by heart rate, blood pressure, and/or symptoms. If such effects occur, the drug may need to be discontinued. ProAir Digihaler, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Adverse Reactions with ArmonAir Digihaler: Most common adverse reactions (greater than or equal to 3%) are: upper respiratory tract infection, nasopharyngitis, oral candidiasis, headache, and cough

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING


INVITING TEAMMATES


Patient Details (2 of 2)

To view a patient's detailed information, select that patient's name from the Patient List.

You will be directed to charts and tables related to the patient's inhaler event data, including:

- The Digihaler® Events Chart
- The Recorded Digihaler® Events Table





IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Do Not Exceed Recommended Dose:** Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Adverse Reactions with AirDuo Digihaler: Most common adverse reactions (greater than or equal to 3%) include nasopharyngitis, oral candidiasis, headache, cough and back pain

Please see additional Safety Information throughout this brochure and full Prescribing Information for <u>ProAir Digihaler ArmonAir Digihaler</u> and <u>AirDuo Digihaler</u>.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS


EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Understanding the Patient Details Screen (1 of 2)

The Patient Details Screen is comprised of three sections:



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Hypersensitivity Reactions including Anaphylaxis: Immediate hypersensitivity reactions may occur after administration of albuterol sulfate, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. Hypersensitivity reactions including anaphylaxis, angioedema, pruritus, and rash have been reported with the use of therapies containing lactose, an inactive ingredient in ProAir Digihaler.

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Serious Asthma-Related Events – Hospitalizations, Intubations, Death: Use of a LABA as monotherapy (without an ICS) for asthma is associated with an increased risk of asthma-related death. Available data from controlled clinical trials also suggest that use of LABA as monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patients. These findings are considered a class effect of LABA monotherapy. When LABA are used in fixed-dose combination with ICS (such as AirDuo Digihaler), data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS


EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Understanding the Patient Details Screen (2 of 2)

The Patient Details Screen is comprised of three sections:



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Coexisting Conditions:** ProAir Digihaler, like all sympathomimetic amines, should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines.

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• **Deterioration of Disease and Acute Episodes:** AirDuo Digihaler should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma. ArmonAir Digihaler and AirDuo Digihaler are not indicated for the relief of acute bronchospasm. An inhaled, short-acting beta2-agonist, not ArmonAir Digihaler or AirDuo Digihaler, should be used to relieve acute symptoms such as shortness of breath

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA


SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

The Digihaler® Events Chart (1 of 3)

The Digihaler Events chart is the first section of the Patient Details Screen. The chart shows a series of stacked columns that count the number of good inhalations (>45 L/min), fair inhalations (30 to 45 L/min), low/no inhalations (<30 L/min), exhalations and blocked air vent events that occurred for the given day.

The events are categorized as:



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Hypokalemia:** As with other beta-agonists, ProAir Digihaler may produce significant hypokalemia in some patients. The decrease is usually transient, not requiring supplementation

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

Avoid Excessive Use and Avoid Use with Other Long acting Beta2-Agonists: AirDuo Digihaler should not be used
more often than recommended, at higher doses than recommended, or in conjunction with other medicines
containing LABA, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been
reported in association with excessive use of inhaled sympathomimetic drugs.
 Patients using AirDuo Digihaler should not use another medicine containing a LABA (e.g., salmeterol, formoterol)

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

fumarate, arformoterol tartrate, indacaterol) for any reason

VIEWING PATIENT DETAILS


EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

The Digihaler® Events Chart (2 of 3)

Here is an example selection of a 30-day view:



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Most common adverse reactions (≥1% and >placebo) are back pain, pain, gastroenteritis viral, sinus headache, urinary tract infection, nasopharyngitis, oropharyngeal pain and vomiting

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• **Oropharyngeal Candidiasis** has occurred in patients treated with ArmonAir Digihaler or AirDuo Digihaler. Advise patients to rinse the mouth with water without swallowing following inhalation

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT

DETAILS


EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

The Digihaler® Events Chart (3 of 3)

Here is an example selection of a 90-day view:



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Drug Interactions:** Other short-acting sympathomimetic bronchodilators should not be used concomitantly with ProAir Digihaler

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Immunosuppression and Risks of Infections: Patients who use corticosteroids, such as found in AirDuo Digihaler and ArmonAir Digihaler are at risk for potential worsening of existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. A more serious or even fatal course of chickenpox or measles may occur in susceptible patients. Use with caution in patients with the above because of the potential for worsening of these infections

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

The Recorded Digihaler® Events Table (1 of 9)

The Recorded Digihaler Events table is the second section of the Patient Details Screen, and provides a different view of patient data in list form. 30-day and 90-day views are available.

Recorded Digihaler Events			W	hat is a Digihaler Event
Date	ProAir Recorded Events	Digihaler ⑦ % Good Inhalations	Daily Self-Assessment ⑦	
04/17 - 04/23/2017	4	0%	5	•
Sat 04/23/2017	1	0%		•
Fri 04/22/2017	-	-	-	,
Thurs 04/21/2017	-	-	©	,
Wed 04/20/2017	-	-	-	,
Tues 04/19/2017	1	0%	<u></u>	,
Mon 04/18/2017	1	0%	(;)	•
Sun 04/17/2017	1	0%	\odot	•
04/10 - 04/16/2017	20	30%	3	•
04/03 - 04/09/2017	21	24%	0	•
03/27 - 04/02/2017	26	19%	2	•
03/25 - 03/26/2017	14	21%	0	•

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

- **Drug Interactions:** (continued)
 - » **Beta-Blockers:** Beta-adrenergic-receptor blocking agents not only block the pulmonary effect of beta-agonists, such as ProAir Digihaler, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Transferring Patients from Systemic Corticosteroid Therapy: Particular care is needed for patients who have been transferred from systemically active corticosteroids to ICS because deaths due to adrenal insufficiency have occurred in patients with asthma during and after transfer from systemic corticosteroids to less systemically available ICS.

Taper patients slowly from systemic corticosteroids if transferring to ArmonAir Digihaler or AirDuo Digihaler

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT

DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

The Recorded Digihaler® Events Table (2 of 9)

Here is an example selection of a collapsed 30-day view:



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

- Drug Interactions: (continued)
 - » **Diuretics:** Caution is advised in the coadministration of beta-agonists with non-potassium sparing diuretics (such as loop or thiazide diuretics). Consider monitoring potassium levels

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• **Hypercorticism and Adrenal Suppression** may occur with high doses of ICS, including fluticasone propionate, or at the recommended dose in susceptible individuals. If such changes occur, discontinue ArmonAir Digihaler or AirDuo Digihaler slowly

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT

DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

The Recorded Digihaler® Events Table (3 of 9)

To see an expanded 30-day view, click on any 7-day date range within this table to see the data for each individual day within the selected period.

	Click the da to expand	ate range					This shows the Daily-Self-Assethe selected 7-	essments
Patient List			Patient, Demo	(MM/DD/YYYY)			0	
30 days ▼ 〈	March 25 2017 - Ap	oril 23, 2017 >	_		LL.	Summarized Data	Detailed Data	
Recorded Digihaler Events							What is a Digih	aler Event?
Date		haler Events ①		haler Events ①	400000000000000000000000000000000000000	gihaler Events ⑦	Daily Self-Assessment	nt ①
	Events	% Good	Events	% Good	Events	% Good		
05/14/2021 - 05/20/2021	-	-	9	+	-	+	0	~
05/07/2021 - 05/13/2021	4	100%	-	-	7	100%	4	•
Thu 05/13/2021	3	100%				-	2	•
Wed 05/12/2021	1	100%	-		1	100%	(3)	•
Tue 05/11/2021	-		-		2	100%	(•
Mon 05/10/2021	-			1,90	2	100%	<u></u>	•
Sun 05/09/2021	-				120	π	-	¥
Sat 05/08/2021	-					-	-	7
Fri 05/07/2021	-				2	100%	(•
04/30/2021 - 05/06/2021	1	100%		160	8	100%	7	•
04/23/2021 - 04/29/2021	5	100%			9	100%	6	•
04/21/2021 - 04/22/2021	-	-	-	*	3	100%	2	

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

- Drug Interactions: (continued)
- » Digoxin: Carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and ProAir Digihaler

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• **Drug Interactions with Strong Cytochrome P450 3A4 Inhibitors:** The use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ritonavir, ketoconazole) with ArmonAir Digihaler or AirDuo Digihaler is not recommended because increased systemic corticosteroid adverse effects may occur; increased cardiovascular adverse effects may also occur with AirDuo Digihaler

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS


EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

The Recorded Digihaler® Events Table (4 of 9)

Here is an example selection of a 90-day view:



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

- Drug Interactions: (continued)
 - » Monoamine Oxidase Inhibitors or Tricyclic Antidepressants: ProAir Digihaler should be administered with extreme caution to patients being treated with these agents, or within 2 weeks of discontinuation of these agents, because the action of albuterol on the cardiovascular system may be potentiated. Consider alternative therapy

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Paradoxical Bronchospasm and Upper Airway Symptoms: Paradoxical bronchospasm may occur. if bronchospasm occurs treat immediately with an inhaled, short-acting bronchodilator discontinue AirDuo Digihaler or ArmonAir Digihaler and institute alternative therapy

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

The Recorded Digihaler® Events Table (5 of 9)

Recorded events for each inhaler, percent of good inhalations, and average daily self assessments.

The table includes:

	The given amoun of time you have						
₹ Patient List		Patient, Demo (MM/DD/YYYY)					
90 days ▼ 〈	January 25, 2017 - April 25,	2017 >		Sumn	narized Data Detailed Data		
Recorded Digihaler Events					What is a Digiha	ler Event?	
Date	Recorded Events	ir Digihaler ② % Good Inhalations	AirDuo Recorded Events	Digihaler ⑦ % Good Inhalations	Daily Self-Assessment ③		
04/17 - 04/23/2017	4	0%	-	-	5	•	
Sat 04/23/2017	1	0%	-	-	<u></u>	•	
Fri 04/22/2017	-	-	-	-	-	•	
Thurs 04/21/2017	-	-	-	-		•	
Wed 04/20/2017	-	-	-	-	-	•	
Tues 04/19/2017	1	0%	-	-	<u>:</u>	•	
Mon 04/18/2017	1	0%	-	-		•	
Sun 04/17/2017	1	0%	-	-	\odot	•	
04/10 - 04/16/2017	20	30%	-	-	3	•	
04/03 - 04/09/2017	21	24%	10	40%	0	•	
03/27 - 04/02/2017	26	19%	9	55%	2	•	
03/25 - 03/26/2017	14	21%	3	66%	0	•	

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Paradoxical Bronchospasm:** ProAir Digihaler can produce paradoxical bronchospasm that may be life-threatening. Discontinue ProAir Digihaler and institute alternative therapy if paradoxical bronchospasm occurs

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Hypersensitivity Reactions, Including Anaphylaxis: Immediate hypersensitivity reactions (e.g., urticaria, angioedema, rash, bronchospasm, hypotension), including anaphylaxis, may occur after administration of ArmonAir Digihaler or AirDuo Digihaler. Discontinue ArmonAir Digihaler or AirDuo Digihaler if such reactions occur

Please see additional Safety Information throughout this brochure and full Prescribing Information for <u>ProAir Digihaler ArmonAir Digihaler</u> and <u>AirDuo Digihaler</u>.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES


The Recorded Digihaler® Events Table (6 of 9)

Recorded events for each inhaler, percent of good inhalations, and average daily self assessments.

The table includes:

Recorded Events

The number of ProAir® Digihalers®, AirDuo® Digihalers® or ArmonAir® Digihalers® Events that were recorded during your selected amount of time since program creation



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Deterioration of Asthma:** Need for more doses of ProAir Digihaler than usual may be a marker of acute or chronic deterioration of asthma and requires reevaluation of treatment, such as possible need for anti-inflammatory treatment, e.g., corticosteroids

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Cardiovascular and Central Nervous System Effects: The salmeterol component of AirDuo Digihaler, can be associated with excessive beta-adrenergic stimulation which could present as the following symptoms: seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, palpitation, nausea, dizziness, fatigue, malaise, and insomnia. Use with caution in patients with cardiac arrhythmias, hypertension, coronary insufficiency. Drug may need to be discontinued in certain patients.

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT

DETAILS

EXPORTING PATIENT DATA


SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

The Recorded Digihaler® Events Table (7 of 9)

Recorded events for each inhaler, percent of good inhalations, and average daily self assessments.

The table includes:



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Use of Anti-Inflammatory Agents: ProAir Digihaler alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Reduction in Bone Mineral Density (BMD): Decreases in BMD have been observed with long-term administration of products containing ICS. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care when using ArmonAir Digihaler or AirDuo Digihaler

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA


SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

The Recorded Digihaler® Events Table (8 of 9)

Recorded events for each inhaler, percent of good inhalations, and average daily self assessments.

The table includes:



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Cardiovascular Effects: ProAir Digihaler, like other beta-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients, as measured by heart rate, blood pressure, and/or symptoms. If such effects occur, the drug may need to be discontinued. ProAir Digihaler, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• **Effect on Growth:** ICS may cause a reduction in growth velocity, Patients should be maintained on the lowest dose of inhaled corticosteroid that effectively controls their asthma. Monitor growth of pediatric patients receiving ArmonAir Digihaler and AirDuo Digihaler.

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT

DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

The Recorded Digihaler® Events Table (9 of 9)

Recorded events for each inhaler, percent of good inhalations, and average daily self assessments.

The table includes:





IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Do Not Exceed Recommended Dose:** Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Glaucoma and Cataracts: Long-term use of ICS, including fluticasone propionate, a component of ArmonAir Digihaler and AirDuo Digihaler, may increase the risk for cataracts or glaucoma. Regular eye exams should be considered

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Digihaler® Connectivity (1 of 7)

The third section of the Patient Details Screen is where you can see a list of ProAir® Digihalers®, AirDuo® Digihalers®, and ArmonAir® Digihalers® that the patient has registered

igihaler Connectivity				Connectivity Help
Digihaler Type	Nickname & ID ②	Added ②	Removed ③	Last Connected ②
ProAir® Digihaler® (albuterol sulfate) Inhalation Powder, 117 mcg	Sports ID: XXXXXXXXXX	03/21/2017	_	1 hour ago
ProAir® Digihaler® (albuterol sulfate) Inhalation Powder, 117 mcg	Travel ID: XXXXXXXXXXX	03/21/2017	_	a month ago
AirDuo® Digihaler® (fluticasone propionate/salmeterol) Inhalation Powder, 113/14 mcg	April ID: XXXXXXXXXX	04/01/2017	_	1 hour ago
AirDuo® Digihaler® (fluticasone propionate/salmeterol) Inhalation Powder, 113/14 mcg	May ID: XXXXXXXXXXX	03/01/2017	04/01/2017	22 days ago

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Hypersensitivity Reactions including Anaphylaxis: Immediate hypersensitivity reactions may occur after administration of albuterol sulfate, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. Hypersensitivity reactions including anaphylaxis, angioedema, pruritus, and rash have been reported with the use of therapies containing lactose, an inactive ingredient in ProAir Digihaler.

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Eosinophilic Conditions and Churg-Strauss Syndrome: Systemic eosinophilic conditions, such as Churg-Strauss syndrome, may occur when using ArmonAir Digihaler or AirDuo Digihaler. Be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT

DETAILS


EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Digihaler® Connectivity (2 of 7)

The table includes:



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Coexisting Conditions: ProAir Digihaler, like all sympathomimetic amines, should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines.

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Coexisting Conditions: Use AirDuo Digihaler with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines

Please see additional Safety Information throughout this brochure and full Prescribing Information for <u>ProAir Digihaler ArmonAir Digihaler</u> and <u>AirDuo Digihaler</u>.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS


EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Digihaler® Connectivity (3 of 7)

The table includes:



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Hypokalemia:** As with other beta-agonists, ProAir Digihaler may produce significant hypokalemia in some patients. The decrease is usually transient, not requiring supplementation

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• **Hypokalemia and Hyperglycemia:** Beta-adrenergic agonist medicines may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. Decrease in serum potassium are usually transient, not requiring supplementation. Be alert to hypokalemia and hyperglycemia in patients using AirDuo Digihaler

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS


EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Digihaler® Connectivity (4 of 7)

The table includes:



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Most common adverse reactions (≥1% and >placebo) are back pain, pain, gastroenteritis viral, sinus headache, urinary tract infection, nasopharyngitis, oropharyngeal pain and vomiting

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Adverse Reactions with ArmonAir Digihaler: Most common adverse reactions (greater than or equal to 3%) are: upper respiratory tract infection, nasopharyngitis, oral candidiasis, headache, and cough

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Digihaler® Connectivity (5 of 7)

The table includes:

		т	Added The date the inhaler was first registered		
gihaler Connectivity				Connectivity Help	
Digihaler Type	Nickname & ID ⑦	Added ⑦	Removed ⑦	Last Connected ②	
ProAir® Digihaler® (albuterol sulfate) Inhalation Powder, 117 mcg	Sports ID: XXXXXXXXXXX	03/21/2017	_	1 hour ago	
ProAir® Digihaler® (albuterol sulfate) Inhalation Powder, 117 mcg	Travel ID: XXXXXXXXXXX	03/21/2017	_	a month ago	
AirDuo® Digihaler® (fluticasone propionate/salmeterol) Inhalation Powder, 113/14 mcg	April ID: XXXXXXXXXX	04/01/2017	-	1 hour ago	
AirDuo® Digihaler® (fluticasone propionate/salmeterol)	May	03/01/2017	04/01/2017	22 days ago	

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Drug Interactions:** Other short-acting sympathomimetic bronchodilators should not be used concomitantly with ProAir Digihaler

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Adverse Reactions with AirDuo Digihaler: Most common adverse reactions (greater than or equal to 3%) include nasopharyngitis, oral candidiasis, headache, cough and back pain

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Digihaler® Connectivity (6 of 7)

The table includes:

				The date the inhaler was removed from the app Pleae Note that a dash indicates the inhaler is currently registered
Digihaler Connectivity				Connectivity Help
Digihaler Type	Nickname & ID ②	Added ⑦	Removed ②	Last Connected ②
ProAir® Digihaler® (albuterol sulfate) Inhalation Powder, 117 mcg	Sports ID: XXXXXXXXXXX	03/21/2017	_	1 hour ago
ProAir® Digihaler® (albuterol sulfate) Inhalation Powder, 117 mcg	Travel	03/21/2017	_	a month ago
AirDuo® Digihaler® (fluticasone propionate/salmeterol) Inhalation Powder, 113/14 mcg	April ID: XXXXXXXXXX	04/01/2017	-	1 hour ago
	May			

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

- Drug Interactions: (continued)
 - » Beta-Blockers: Beta-adrenergic-receptor blocking agents not only block the pulmonary effect of beta-agonists, such as ProAir Digihaler, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Serious Asthma-Related Events – Hospitalizations, Intubations, Death: Use of a LABA as monotherapy (without an ICS) for asthma is associated with an increased risk of asthma-related death. Available data from controlled clinical trials also suggest that use of LABA as monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patients. These findings are considered a class effect of LABA monotherapy. When LABA are used in fixed-dose combination with ICS (such as AirDuo Digihaler), data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Digihaler® Connectivity (7 of 7)

The table includes:

gihaler Connectivity				
Digihaler Type	Nickname & ID ⑦	Added ②	Removed ?	Last Connected ②
ProAir® Digihaler® (albuterol sulfate) Inhalation Powder, 117 mcg	Sports ID: XXXXXXXXXXX	03/21/2017	_	1 hour ago
ProAir® Digihaler® (albuterol sulfate) Inhalation Powder, 117 mcg	Travel ID: XXXXXXXXXX	03/21/2017	_	a month ago
AirDuo® Digihaler® (fluticasone propionate/salmeterol) Inhalation Powder, 113/14 mcg	April ID: XXXXXXXXXX	04/01/2017	_	1 hour ago
AirDuo® Digihaler® (fluticasone propionate/salmeterol) Inhalation Powder, 113/14 mcg	May ID: XXXXXXXXXXX	03/01/2017	04/01/2017	22 days ago

Last Connected

Indicates the last known time that the patient's ProAir® Digihalers®, AirDuo® Digihalers®, and/or ArmonAir® Digihalers® were connected to the app

Please Note that this information will only be the most up-to-date if the inhaler is connected to the Digihaler App and the patient's Bluetooth® Wireless Technology is turned on and within range

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

- **Drug Interactions:** (continued)
 - » **Diuretics:** Caution is advised in the coadministration of beta-agonists with non-potassium sparing diuretics (such as loop or thiazide diuretics). Consider monitoring potassium levels

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

Deterioration of Disease and Acute Episodes: AirDuo Digihaler should not be initiated in patients during rapidly
deteriorating or potentially life-threatening episodes of asthma. ArmonAir Digihaler and AirDuo Digihaler are not
indicated for the relief of acute bronchospasm. An inhaled, short-acting beta₂-agonist, not ArmonAir Digihaler or AirDuo
Digihaler, should be used to relieve acute symptoms such as shortness of breath

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS


EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Accessing Detailed Data

At the top right of the Patient Details Screen, you will be able to toggle between the **"Summarized Data"** and **"Detailed Data"** screens.



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

- **Drug Interactions:** (continued)
 - » Digoxin: Carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and ProAir Digihaler

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

- Avoid Excessive Use and Avoid Use with Other Long acting Beta2-Agonists: AirDuo Digihaler should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.
- Patients using AirDuo Digihaler should not use another medicine containing a LABA (e.g., salmeterol, formoterol fumarate, arformoterol tartrate, indacaterol) for any reason

Please see additional Safety Information throughout this brochure and full Prescribing Information for <u>ProAir Digihaler ArmonAir Digihaler</u> and <u>AirDuo Digihaler</u>.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

The Peak Inspiratory Flow Chart

The **Peak Inspiratory Flow** (PIF) chart will present specific Peak Inspiratory Flow Rate values in Liters/minute over a 30 or 90-day period from 30-90 L/min (ProAir® Digihaler®) and 30-120 L/min (AirDuo® Digihaler® and ArmonAir® Digihaler®). Inhalations that fall outside this range are counted in distinct categories surrounding the chart.



Provided at least 10 inhalations are plotted, a trend line will be displayed to help the user identify trends in the values. The trend line will use a locally estimated scatterplot smoothing algorithm (LOESS) with a smoothing factor of 0.5. PIF rate accuracy above 90 L/min has not been fully verified.

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

- Drug Interactions: (continued)
 - » Monoamine Oxidase Inhibitors or Tricyclic Antidepressants: ProAir Digihaler should be administered with extreme caution to patients being treated with these agents, or within 2 weeks of discontinuation of these agents, because the action of albuterol on the cardiovascular system may be potentiated. Consider alternative therapy

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• **Oropharyngeal Candidiasis** has occurred in patients treated with ArmonAir Digihaler or AirDuo Digihaler. Advise patients to rinse the mouth with water without swallowing following inhalation

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

The Inhalation Volume Chart

The **Inhalation Volume** chart will present specific Inhalation Volume values in Liters over a 30 or 90-day period, based on Digihaler® events from 0.4 - 4.0 L. Inhalations that fall outside this range are counted in distinct categories surrounding the chart.



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Paradoxical Bronchospasm:** ProAir Digihaler can produce paradoxical bronchospasm that may be life-threatening. Discontinue ProAir Digihaler and institute alternative therapy if paradoxical bronchospasm occurs

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Immunosuppression and Risks of Infection: Patients who use corticosteroids, such as found in AirDuo Digihaler and ArmonAir Digihaler are at risk for potential worsening of existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. A more serious or even fatal course of chickenpox or measles may occur in susceptible patients. Use with caution in patients with the above because of the potential for worsening of these infections

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING


INVITING TEAMMATES

Section 5: Exporting Patient Data

Setting up an Export (1 of 4)

From the Patient List, the Digihaler® Dashboard allows you to export Patient Inhaler Event Data for all of your patients enrolled in the program. This allows healthcare providers to download reports and bring them to consultations to view with their patients.

Please Note that the file contains patient data and the user should handle this information per their policies



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Deterioration of Asthma:** Need for more doses of ProAir Digihaler than usual may be a marker of acute or chronic deterioration of asthma and requires reevaluation of treatment, such as possible need for anti-inflammatory treatment, e.g., corticosteroids

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Transferring Patients from Systemic Corticosteroid Therapy: Particular care is needed for patients who have been transferred from systemically active corticosteroids to ICS because deaths due to adrenal insufficiency have occurred in patients with asthma during and after transfer from systemic corticosteroids to less systemically available ICS. Taper patients slowly from systemic corticosteroids if transferring to ArmonAir Digihaler or AirDuo Digihaler

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA


SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Setting up an Export (2 of 4)

You will be prompted to select the date range for all patients' inhaler event data.

No selection is made by default.



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Use of Anti-Inflammatory Agents: ProAir Digihaler alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• **Hypercorticism and Adrenal Suppression** may occur with high doses of ICS, including fluticasone propionate, or at the recommended dose in susceptible individuals. If such changes occur, discontinue ArmonAir Digihaler or AirDuo Digihaler slowly

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA


SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Setting up an Export (3 of 4)

You will be prompted to select the date range for all patients' inhaler event data.

No selection is made by default.



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Cardiovascular Effects: ProAir Digihaler, like other beta-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients, as measured by heart rate, blood pressure, and/or symptoms. If such effects occur, the drug may need to be discontinued. ProAir Digihaler, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Drug Interactions with Strong Cytochrome P450 3A4 Inhibitors: The use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ritonavir, ketoconazole) with ArmonAir Digihaler or AirDuo Digihaler is not recommended because increased systemic corticosteroid adverse effects may occur; increased cardiovascular adverse effects may also occur with AirDuo Digihaler

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS


EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Setting up an Export (4 of 4)

You will then see "Exporting Data" at the top right side of your Dashboard view.



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Do Not Exceed Recommended Dose:** Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Paradoxical Bronchospasm and Upper Airway Symptoms: Paradoxical bronchospasm may occur. if bronchospasm occurs treat immediately with an inhaled, short-acting bronchodilator discontinue AirDuo Digihaler or ArmonAir Digihaler and institute alternative therapy

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA


SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Applying Filters

Rather than exporting data for all patients, you have the option to apply filters to the Patient List and export data for a smaller group. Search by patient name if you would like to export data for an individual patient.

Please Note: Once a filter is applied, the user can click an X icon to clear the filter and return to the Patient List containing all patients.



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Hypersensitivity Reactions including Anaphylaxis: Immediate hypersensitivity reactions may occur after administration of albuterol sulfate, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. Hypersensitivity reactions including anaphylaxis, angioedema, pruritus, and rash have been reported with the use of therapies containing lactose, an inactive ingredient in ProAir Digihaler.

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Hypersensitivity Reactions, Including Anaphylaxis: Immediate hypersensitivity reactions (e.g., urticaria, angioedema, rash, bronchospasm, hypotension), including anaphylaxis, may occur after administration of ArmonAir Digihaler or AirDuo Digihaler. Discontinue ArmonAir Digihaler or AirDuo Digihaler if such reactions occur

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

filters are available.

PROGRAM SETTINGS

. . . .

Section 6: Support and Troubleshooting

If you need further assistance with the Digihaler® Dashboard, or if you have any questions or concerns:

- Visit our <u>Support Center</u>
- Call customer assistance at 1-(833) 390-2147

If you're having issues accessing the Dashboard, check that your browser/system requirements meet the guidelines below:

Browser Requirements











System Requirements

- 1110 pixel width is required to view all data.
- It is recommended that your screen resolution be set to 1280 x 800.
- U.S. English is the only supported language.
- The time is hard-coded to a 12-hour AM/PM display.



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Coexisting Conditions: ProAir Digihaler, like all sympathomimetic amines, should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines.

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Cardiovascular and Central Nervous System Effects: The salmeterol component of AirDuo Digihaler, can be associated with excessive beta-adrenergic stimulation which could present as the following symptoms: seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, palpitation, nausea, dizziness, fatigue, malaise, and insomnia. Use with caution in patients with cardiac arrhythmias, hypertension, coronary insufficiency. Drug may need to be discontinued in certain patients.

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING


INVITING TEAMMATES

For Dashboard Admins and Super Admins

Section 7: Inviting Teammates

Managing your Program Together (1 of 4)

You can invite teammates to help you manage your specific program. Different teammates are provided different permissions (See Dashboard Team section). Be sure to choose teammates who will be the best fit for each role. When you log into your program, "Patient List" will be your default view (as shown).



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Hypokalemia:** As with other beta-agonists, ProAir Digihaler may produce significant hypokalemia in some patients. The decrease is usually transient, not requiring supplementation

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Reduction in Bone Mineral Density (BMD): Decreases in BMD have been observed with long-term administration of products containing ICS. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care when using ArmonAir Digihaler or AirDuo Digihaler

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA


SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES PROGRAM SETTINGS

• • • • •

Managing your program together (2 of 4)

After the Super Administrator or Administrator on the team has set up their profile and signed in, they can begin to invite other teammates:



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Most common adverse reactions (≥1% and >placebo) are back pain, pain, gastroenteritis viral, sinus headache, urinary tract infection, nasopharyngitis, oropharyngeal pain and vomiting

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• **Effect on Growth:** ICS may cause a reduction in growth velocity, Patients should be maintained on the lowest dose of inhaled corticosteroid that effectively controls their asthma. Monitor growth of pediatric patients receiving ArmonAir Digihaler and AirDuo Digihaler.

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS


EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Managing your program together (3 of 4)

After the Super Administrator or Administrator on the team has set up their profile and signed in, they can begin to invite other teammates:



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Drug Interactions:** Other short-acting sympathomimetic bronchodilators should not be used concomitantly with ProAir Digihaler

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Glaucoma and Cataracts: Long-term use of ICS, including fluticasone propionate, a component of ArmonAir Digihaler and AirDuo Digihaler, may increase the risk for cataracts or glaucoma. Regular eye exams should be considered

Please see additional Safety Information throughout this brochure and full Prescribing Information for <u>ProAir Digihaler ArmonAir Digihaler</u> and <u>AirDuo Digihaler</u>.

ACCOUNT BASICS INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING


INVITING TEAMMATES

PROGRAM SETTINGS

• • • • • •

Managing your program together (4 of 4)

After the Super Admin or Admin on the team has set up their profile and signed in, they can begin to invite other teammates.



After clicking the "Invite Teammate" button, an invitation link along with the invited Teammate's account email will be generated by the Digihaler® Dashboard. The Dashboard does not send this information. You will need to copy, paste, and send this information to your teammate via the communication of your choice. The newly invited teammate will use this information to create their own credentials in the system. If the teammate you've invited has previously completed registration, they will be prompted to join your program immediately following their next sign in.

Please Note:

- The invitation code will expire after 30 days
- To join your program, the teammate must sign up using the same email you entered in the "Invite Teammate" form

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

- Drug Interactions: (continued)
 - » **Beta-Blockers:** Beta-adrenergic-receptor blocking agents not only block the pulmonary effect of beta-agonists, such as ProAir Digihaler, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Eosinophilic Conditions and Churg-Strauss Syndrome: Systemic eosinophilic conditions, such as Churg-Strauss syndrome, may occur when using ArmonAir Digihaler or AirDuo Digihaler. Be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT

DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Changing the Role of a Teammate


If a user's role needs to be changed, Super Admins and Admins can directly change an existing user's role provided they are not elevating a user beyond their own role. Please refer to <u>Section 1</u> of this Reference Guide for a breakdown of role responsibilities.

A Super Admin can...

- Promote Dashboard User to Admin or Super Admin
- Promote Admin to Super Admin
- Demote Super Admin to Admin or Dashboard User
- Demote Admin to Dashboard User

An Admin can...

- Promote Dashboard User to Admin
- Demote Admin to Dashboard User



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

- Drug Interactions: (continued)
 - » **Diuretics:** Caution is advised in the coadministration of beta-agonists with non-potassium sparing diuretics (such as loop or thiazide diuretics). Consider monitoring potassium levels

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Coexisting Conditions: Use AirDuo Digihaler with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING


INVITING TEAMMATES

PROGRAM SETTINGS

CR Digihaler Dashboard Guide V1: Aug 21

Managing Pending Invitations

You can view and manage pending invitations for teammates to the Dashboard by clicking the Pending Invitations tab on the Team List page. Click to renew the 30 day validity period of the invitation, cancel the invitation, or change the role of an invited teammate. This feature is only available for Admins or Super Admins.



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

- Drug Interactions: (continued)
 - » **Digoxin:** Carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and ProAir Digihaler

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• **Hypokalemia and Hyperglycemia:** Beta-adrenergic agonist medicines may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. Decrease in serum potassium are usually transient, not requiring supplementation. Be alert to hypokalemia and hyperglycemia in patients using AirDuo Digihaler

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING


INVITING TEAMMATES

Exporting an Audit Log

If you are looking for a detailed report of teammate activity within your healthcare program, an Admin or Super Admin can choose to export an Audit Log CSV file. With this report, you will be able to view specific actions taken by your teammates including: login, logout, joined program, invited patient, downloaded patient data, etc.

For each action, you will be able to view what the action was, which user took the action, when the action occurred, etc.

The Audit Log is sorted by date and time. When exporting the Audit Log, you will have the option to customize the date range of exported data if you should choose.



Click here to export the Audit Log.

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

- Drug Interactions: (continued)
 - » Monoamine Oxidase Inhibitors or Tricyclic Antidepressants: ProAir Digihaler should be administered with extreme caution to patients being treated with these agents, or within 2 weeks of discontinuation of these agents, because the action of albuterol on the cardiovascular system may be potentiated. Consider alternative therapy

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Adverse Reactions with ArmonAir Digihaler: Most common adverse reactions (greater than or equal to 3%) are: upper respiratory tract infection, nasopharyngitis, oral candidiasis, headache, and cough

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING


INVITING TEAMMATES

For Dashboard Admins and Super Admins

Section 8: Program Settings

Program Settings

The Program Settings page allows Admin users to create custom filters that all members of their program can leverage to filter the Patient List.



Super Admins and Admins will be able to access the Program Settings screen. From here they can add, remove or edit filters.

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Paradoxical Bronchospasm: ProAir Digihaler can produce paradoxical bronchospasm that may be lifethreatening. Discontinue ProAir Digihaler and institute alternative therapy if paradoxical bronchospasm occurs

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Adverse Reactions with AirDuo Digihaler: Most common adverse reactions (greater than or equal to 3%) include nasopharyngitis, oral candidiasis, headache, cough and back pain

Please see additional Safety Information throughout this brochure and full Prescribing Information for <u>ProAir Digihaler ArmonAir Digihaler</u> and <u>AirDuo Digihaler</u>.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA


SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Configuring Filters (1 of 3)

When defining a new filter:

- 1. Start by clicking "Create Filter"
- 2. Give the filter a name
- 3. Set Filter criteria:
 - a. Choose at least one brand to consider
 - b. Choose a time of day when events may have occurred
 - c. Choose a date range
 - d. Choose the threshold condition ("is greater than", "is less than", or "compared to")
 - e. Choose the numerical threshold
- 4. Click "Save Filter"



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Deterioration of Asthma:** Need for more doses of ProAir Digihaler than usual may be a marker of acute or chronic deterioration of asthma and requires reevaluation of treatment, such as possible need for anti-in flammatory treatment, e.g., corticosteroids

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Serious Asthma-Related Events - Hospitalizations, Intubations, Death: Use of AirDuo Digihaler, LABA as monotherapy (without an ICS) for asthma is associated with an increased risk of asthma-related death. Available data from controlled clinical trials also suggest that use of LABA as monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patients. These findings are considered a class effect of LABA monotherapy. When LABA are used in fixed-dose combination with ICS (such as AirDuo Digihaler), data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone

Please see additional Safety Information throughout this brochure and full Prescribing Information for <u>ProAir Digihaler ArmonAir Digihaler</u> and <u>AirDuo Digihaler</u>.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA


SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Configuring Filters (2 of 3)

By selecting the "Condition" drop down and selecting "is greater than" or "is less than", filters can be set up to display patients in the Patient List that are over or under a set threshold, defined by the number of events that occurred within the specified time frame.

In the example below, only patients with AirDuo® Digihaler® Events that occurred within the last month would appear when applying this filter in the Patient List.



Configuring filters allows users to compare:

- how events changed over time from one week to another
- daytime vs nighttime events
- inhaler brands or inhalation categories

IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Use of Anti-Inflammatory Agents: ProAir Digihaler alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• **Deterioration of Disease and Acute Episodes:** AirDuo Digihaler should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma. ArmonAir Digihaler and AirDuo Digihaler are not indicated for the relief of acute bronchospasm. An inhaled, short-acting beta₂-agonist, not ArmonAir Digihaler or AirDuo Digihaler, should be used to relieve acute symptoms such as shortness of breath

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING


INVITING TEAMMATES

Configuring Filters (3 of 3)

By selecting the "Condition" drop down and selecting "compared to", the user can specify a second group of events, and then specify the relationship between the two groups in terms of percent difference.

In the example below, the number of AirDuo® Digihaler® events are being compared from the last month, to the month prior. If the number of AirDuo Digihaler events of the past month are 30% higher than the month prior, the patient is included when applying the filter in the Patient List.

In this example, by selecting the "Condition" drop down and selecting "compared to", you can view how different one group of events are compared to another group of events.



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• Cardiovascular Effects: ProAir Digihaler, like other beta-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients, as measured by heart rate, blood pressure, and/or symptoms. If such effects occur, the drug may need to be discontinued. ProAir Digihaler, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Avoid Excessive Use and Avoid Use with Other Long acting Beta2-Agonists: AirDuo Digihaler should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.

Patients using AirDuo Digihaler should not use another medicine containing a LABA (e.g., salmeterol, formoterol fumarate, arformoterol tartrate, indacaterol) for any reason

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA


SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES

Using Filters

Once a filter has been configured and saved from the Programs Settings page, it immediately becomes visible to all users of the program. Provided at least one filter has been created, the option to filter will appear on the Patient List.

By default, the Patient List will display an un filtered list with All Patients data. To filter the Patient List, select the Filter button and choose the desired filter from the dropdown menu. Once a filter is selected, the Patient List will adjust based on the filter and the specific inhalations of patient population. An X icon allows users to clear the filter and return to the Patient List containing all patients.



IMPORTANT SAFETY INFORMATION FOR PROAIR® DIGIHALER® (CONTINUED)

• **Do Not Exceed Recommended Dose:** Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma

IMPORTANT SAFETY INFORMATION FOR ARMONAIR® DIGIHALER® AND AIRDUO® DIGIHALER® (CONTINUED)

• Oropharyngeal Candidiasis has occurred in patients treated with ArmonAir Digihaler or AirDuo Digihaler. Advise patients to rinse the mouth with water without swallowing following inhalation

Please see additional Safety Information throughout this brochure and full Prescribing Information for ProAir Digihaler ArmonAir Digihaler and AirDuo Digihaler.

ACCOUNT BASICS

INVITING PATIENTS

NAVIGATING THE PATIENT LIST

VIEWING PATIENT DETAILS

EXPORTING PATIENT DATA

SUPPORT AND TROUBLESHOOTING

INVITING TEAMMATES PROGRAM SETTINGS

• • • •

References: 1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2020. https://www.ginasthma.org. Accessed on July 7, 2020. 2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2020. https://goldcopd.org. Accessed on July 7, 2020 3. ProAir Digihaler Prescribing Information. Parsippany, NJ: Teva Respiratory, LLC. 4. AirDuo Digihaler Prescribing Information. Parsippany, NJ: Teva Respiratory, LLC. 5. ArmonAir Digihaler Prescribing Information. Parsippany, NJ: Teva Respiratory, LLC. © 2023 Teva Respiratory, LLC. ADH-41095 08/2023